[go: up one dir, main page]

WO2009005033A1 - 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤 - Google Patents

神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤 Download PDF

Info

Publication number
WO2009005033A1
WO2009005033A1 PCT/JP2008/061834 JP2008061834W WO2009005033A1 WO 2009005033 A1 WO2009005033 A1 WO 2009005033A1 JP 2008061834 W JP2008061834 W JP 2008061834W WO 2009005033 A1 WO2009005033 A1 WO 2009005033A1
Authority
WO
WIPO (PCT)
Prior art keywords
neuropathy
agent
improving
dysfunction due
dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061834
Other languages
English (en)
French (fr)
Inventor
Kenji Kadomatsu
Yukihiro Matsuyama
Akiomi Tanaka
Sawako Takeshita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya University NUC
Seikagaku Corp
Original Assignee
Nagoya University NUC
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya University NUC, Seikagaku Corp filed Critical Nagoya University NUC
Priority to EP08790747A priority Critical patent/EP2174661B1/en
Priority to JP2009521624A priority patent/JP5341756B2/ja
Priority to US12/667,178 priority patent/US20110059508A1/en
Publication of WO2009005033A1 publication Critical patent/WO2009005033A1/ja
Anticipated expiration legal-status Critical
Priority to US13/778,359 priority patent/US8754036B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　本発明の課題は、神経障害に基づく機能不全の改善の有効成分となり得る物質を提供することである。その解決手段としての本発明の神経障害に基づく機能不全の改善剤は、ケラタン硫酸糖鎖骨格中のＮ－アセチルグルコサミニド結合を加水分解するエンド－β－Ｎ－アセチルグルコサミニダーゼ型酵素を有効成分とすることを特徴とする。本発明改善剤を投与することにより、治療対象の運動神経機能不全や、アロデニアや痛覚過敏反応に基づく疼痛に代表される神経因性疼痛等の知覚神経機能不全において臨床的な改善が得られる。
PCT/JP2008/061834 2007-06-29 2008-06-30 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤 Ceased WO2009005033A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08790747A EP2174661B1 (en) 2007-06-29 2008-06-30 Agent for improving neuropathic pain
JP2009521624A JP5341756B2 (ja) 2007-06-29 2008-06-30 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤
US12/667,178 US20110059508A1 (en) 2007-06-29 2008-06-30 Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
US13/778,359 US8754036B2 (en) 2007-06-29 2013-02-27 Method for treating neuropathic pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007173487 2007-06-29
JP2007-173487 2007-06-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/667,178 A-371-Of-International US20110059508A1 (en) 2007-06-29 2008-06-30 Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
US13/778,359 Division US8754036B2 (en) 2007-06-29 2013-02-27 Method for treating neuropathic pain

Publications (1)

Publication Number Publication Date
WO2009005033A1 true WO2009005033A1 (ja) 2009-01-08

Family

ID=40226077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061834 Ceased WO2009005033A1 (ja) 2007-06-29 2008-06-30 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤

Country Status (4)

Country Link
US (2) US20110059508A1 (ja)
EP (1) EP2174661B1 (ja)
JP (1) JP5341756B2 (ja)
WO (1) WO2009005033A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
RS61683B1 (sr) 2010-06-25 2021-05-31 Shire Human Genetic Therapies Isporuka terapijskih agenasa u centralni nervni sistem
EP3421989A4 (en) * 2016-02-24 2019-08-14 Osaka University Test method

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
JP2726274B2 (ja) 1988-08-24 1998-03-11 生化学工業株式会社 新規ケラタン硫酸分解酵素並びにそれを生産する微生物及び方法
US5763205A (en) 1992-06-26 1998-06-09 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Producing pure chondroitinase ABC from Proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US5840546A (en) 1994-11-22 1998-11-24 Seikagaku Corporation Keratin sulfate hydrolase obtainable by using Bacillus circulans and method for producing same
JP2004024189A (ja) 2002-06-28 2004-01-29 Seikagaku Kogyo Co Ltd 耐熱性ケラタナーゼをコードするｄｎａ
WO2004103299A2 (en) 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
US20060233782A1 (en) 2003-05-16 2006-10-19 Gruskin Elliott A Proteoglycan degrading mutants for the treatment of CNS
JP2006290842A (ja) 2005-04-14 2006-10-26 Univ Nagoya 神経障害の予防又は治療剤
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0493533A4 (en) * 1989-10-27 1992-10-28 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
HUT77134A (hu) * 1994-12-01 1998-03-02 Seikagaku Corporation Keratán-szulfát-oligoszacharid frakciók és ilyet tartalmazó gyógyszerkészítmények és eljárás a fenti oligoszaharidok előállítására
EP0869362B1 (en) * 1997-04-04 2004-08-18 Seikagaku Corporation Quantitative determination method for heparan sulfate and diagnostic method using the same
KR20040077928A (ko) * 2002-01-31 2004-09-07 와이어쓰 아그레카나제 분자
AU2003261269A1 (en) * 2002-07-29 2004-02-16 Wyeth Modified adamts4 molecules and method of use thereof
CA2556161A1 (en) * 2004-01-30 2005-08-18 Emory University Heparan-sulfate proteoglycan degrading enzymes for promotion of nerve regeneration
EP1737953A2 (en) * 2004-04-16 2007-01-03 Wyeth a Corporation of the State of Delaware Adamts-8 proteins and uses thereof
ES2345216T3 (es) * 2005-01-18 2010-09-17 Meiji Dairies Corporation Agente terapeutico para trastornos sensoriales.
JP2009091248A (ja) * 2006-01-17 2009-04-30 Toshitsu Kagaku Kenkyusho:Kk 外傷性神経障害および／または運動機能障害の治療薬

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2726274B2 (ja) 1988-08-24 1998-03-11 生化学工業株式会社 新規ケラタン硫酸分解酵素並びにそれを生産する微生物及び方法
US5763205A (en) 1992-06-26 1998-06-09 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Producing pure chondroitinase ABC from Proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US6184023B1 (en) 1992-06-26 2001-02-06 Seikgaka Corporation Chondroitinase, process for preparing the same, and pharmaceutical composition comprising the same
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
JP3734504B2 (ja) 1994-11-22 2006-01-11 生化学工業株式会社 新規なケラタン硫酸分解酵素
EP0798376B1 (en) 1994-11-22 2004-02-18 Seikagaku Corporation Novel keratan sulfate hydrolase
US5840546A (en) 1994-11-22 1998-11-24 Seikagaku Corporation Keratin sulfate hydrolase obtainable by using Bacillus circulans and method for producing same
JP2004024189A (ja) 2002-06-28 2004-01-29 Seikagaku Kogyo Co Ltd 耐熱性ケラタナーゼをコードするｄｎａ
WO2004103299A2 (en) 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
US20060233782A1 (en) 2003-05-16 2006-10-19 Gruskin Elliott A Proteoglycan degrading mutants for the treatment of CNS
JP2007520447A (ja) 2003-05-16 2007-07-26 アコーダ セラピューティクス、インク． 中枢神経系障害を治療するための組成物および方法
JP2006290842A (ja) 2005-04-14 2006-10-26 Univ Nagoya 神経障害の予防又は治療剤

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BASSO, D. M.; BEATTIE, M. S.; BRESNAHAN, J. C.: "Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection", EXP. NEUROL., vol. 139, 1996, pages 244 - 256
CHAPLAN, S. R.; BACH, F. W.; POGREL, J. W.; CHUNG, J. M.; YAKSH, T. L.: "Quantitative assessment of tactile allodynia in the rat paw.", J. NEUROSCI. METHODS, vol. 53, 1994, pages 55 - 63
HAMAI A. ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 9123 - 9130
HONDA, S. ET AL.: "Extracellular ATP or ADP Induce Chemotaxis of Cultured Microglia through Gi/o-Coupled P2Y Receptors", J. NEUROSCI., vol. 21, no. 6, 2001, pages 1975 - 1982
KIYOSHI NAKAZAWA; SAKARU SUZUKI, J. BIOL. CHEM., vol. 250, no. 3, 1975, pages 912 - 917
NIEDEROST, B. P.; ZIMMERMANN, D. R.; SCHWAB, M. E.; BANDTLOW, C. E.: "Bovine CNS myelin contains neurite growth-inhibitory activity associated with chondroitin sulfate proteoglycans", J. NEUROSCI., vol. 19, 1999, pages 8979 - 8989
See also references of EP2174661A4 *
YAMAGATA, T. ET AL., J. BIOL. CHEM., vol. 243, 1968, pages 1523 - 1535

Also Published As

Publication number Publication date
US8754036B2 (en) 2014-06-17
US20130164276A1 (en) 2013-06-27
JP5341756B2 (ja) 2013-11-13
EP2174661A1 (en) 2010-04-14
JPWO2009005033A1 (ja) 2010-08-26
EP2174661B1 (en) 2012-12-19
EP2174661A4 (en) 2011-11-02
US20110059508A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007067504A3 (en) Lactam compounds and methods of using the same
WO2010001169A3 (en) Chemical compounds 251
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2007042261A3 (en) Compositions comprising cross-species-specific antibodies and uses thereof
WO2007137164A3 (en) Co-therapy for the treatment of epilepsy and related disorders
WO2005102294A3 (de) Gegen missbrauch gesichertes transdermales system
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
WO2010074588A3 (en) Pharmaceutical compounds
EP2081550A4 (en) COATING OF CAPSULES WITH PHARMACEUTICAL ACTIVE SUBSTANCES
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
WO2006002971A3 (en) Nucleic acids for the treatment of hmgb1-related pathologies
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2007144493A3 (fr) Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
WO2007061862A3 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
EP2143719A4 (en) PHARMACEUTICAL COMPOSITION, FOOD OR BEVERAGE THAT IS CAPABLE OF IMPROVING THE ACTIVITY OF SYMPATHETIC NERVES
EP1920774A4 (en) COMPOSITION WITH FUCOIDAN OR FUCOIDAN HYDROLYSATE AND IMMUNO-POTENTRIC MATERIAL
WO2007142986A3 (en) Aminothiazole derivatives and their uses as antibacterial agents
WO2009121496A3 (en) Use of a biologically active blood serum for the treatment of a disorder charcterized in a reduced function of a gaba receptor
WO2009005033A1 (ja) 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤
EP1905452A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
WO2010042530A3 (en) Nlrc5 as a target for immune therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790747

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009521624

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008790747

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12667178

Country of ref document: US